BICYCLE THERAPEUTICS PLC (BCYC) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-06

Key Insights

Insider Michael Skynner, the Chief Scientific Officer, sold a total of 2,404 ordinary shares of Bicycle Therapeutics PLC on April 2 and April 6, 2026 at a weighted average price of $4.91 and $5.05 per share, respectively.
The shares sold were to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs), which is a mandatory 'sell-to-cover' transaction and not a discretionary sale.
Following the reported transactions, Skynner still holds a direct beneficial ownership of 159,562 ordinary shares in the company.

Want the newest filings?

This analysis covers the filing from 2026-04-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-06

The CEO, Kevin Lee, sold a total of 7,683 shares of Bicycle Therapeutics PLC (BCYC) on April 2nd and April 6th, 2026 at weighted average prices of $4.91 and $5.05 respectively.
The sales were made to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs), and not discretionary sales.
After the reported transactions, the CEO still holds 611,313 ordinary shares of the company, indicating he maintains a significant equity stake.

Filed: 2026-04-06

Jennifer Scott Perry, the Chief Operating Officer of Bicycle Therapeutics PLC, made sales of the company's ordinary shares on April 2, 2026 and April 6, 2026, likely to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs).
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025, indicating a pre-planned nature of the transactions.
The total number of shares sold was 1,408, representing a minor reduction in Perry's direct beneficial ownership from 92,834 shares to 92,464 shares.

Filed: 2026-04-06

The reporting person, Travis Thompson, sold 799 ordinary shares on April 2, 2026 and 102 ordinary shares on April 6, 2026, likely to cover statutory tax withholding obligations related to the vesting and settlement of his restricted stock units (RSUs).
The reported sales represent a small fraction (less than 1%) of the reporting person's total beneficial ownership of 65,364 ordinary shares, indicating the transactions were routine in nature.
The reporting person's role as the Chief Financial Officer suggests the share sales were not driven by negative sentiment towards the company's performance or prospects.

Filed: 2026-04-06

Reporting person Michael Charles Ferguson, the Chief Product and Supply Chain Officer of Bicycle Therapeutics PLC, sold 1,772 ordinary shares on April 2 and April 6, 2026 to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs).
The shares were sold at weighted average prices of $4.91 and $5.05, respectively, and the reporting person continues to beneficially own 96,136 ordinary shares.
The sale of shares to cover tax withholding obligations is a routine transaction and does not necessarily indicate a change in the reporting person's long-term outlook on the company.

Filed: 2026-02-04

Travis Thompson, the Chief Financial Officer of Bicycle Therapeutics PLC, has been granted a stock option to acquire 58,000 ordinary shares of the company at an exercise price of $6.49 per share.
The option will vest over a four-year period, with the first 25% vesting on February 3, 2027 and the remaining shares vesting in 36 equal monthly installments thereafter.
This option grant represents a vote of confidence in Thompson's leadership and aligns his interests with those of the company and its shareholders.

Filed: 2026-01-06

Baker Bros. Advisors LP, a 10% owner of Bicycle Therapeutics PLC (BCYC), has acquired 38,000 new share options and 38,000 additional American Depositary Shares (ADSs) through the company's 2020 Equity Incentive Plan.
The new share options and ADS acquisitions suggest continued long-term confidence and commitment from a major institutional investor in the company.
The vesting schedule of the restricted share units (RSUs) granted to Felix J. Baker, a managing member of Baker Bros. Advisors, aligns his interests with long-term shareholder value creation.

Filed: 2026-01-06

The reporting person, Robert Charles Swanton, was granted 3,726 restricted share units (RSUs) that will vest over the next year.
Swanton was also granted 7,453 stock options that will vest over the next year, indicating an alignment of interests with shareholders.
The insider acquisition of shares and options suggests a positive outlook on the company's future prospects.

Filed: 2026-01-06

The reporting person, Jose-Carlos Gutierrez-Ramos, acquired 9,500 ordinary shares of Bicycle Therapeutics PLC through a restricted share unit (RSU) award, indicating an increase in his beneficial ownership of the company's stock.
The reporting person was also granted 19,000 stock options with an exercise price of $7.08, which will vest in four equal installments over the next year.
The insider transactions suggest a positive sentiment towards the company's prospects, as the reporting person, who is a director, is increasing his ownership stake.

Filed: 2026-01-06

The reporting person, Janice Bourque, was granted 9,500 restricted share units (RSUs) and 19,000 stock options on January 2, 2026. This indicates that the company is incentivizing its director through equity-based compensation.
The RSUs and stock options will vest in four equal installments over the course of 2026, suggesting the company is providing long-term incentives to the director.
The exercise price of the stock options is $7.08, which is the current market price of the company's ordinary shares, indicating the options are granted at-the-money.

Other reports for BICYCLE THERAPEUTICS PLC

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.